Reported 8 months ago
Jisheng Life Sciences actively laid out its stock public offering, expanding share capital to over 400 million yuan after completing the final round of public fundraising in February, obtaining a 3,000-square-meter industrial area in Miaoli in March to develop new nuclear medicine products, new products, and a new production base in the future, aiming to become the first domestically capital market-listed professional nuclear medicine PIC/S GMP plant. With rapid advancements in nuclear medicine imaging diagnosis and treatment technologies, nuclear medicine products are seen as a new blue ocean in the pharmaceutical industry. Jisheng Life Sciences' CEO Lin Liangguang pointed out that in the past year, international pharmaceutical giants such as Bayer and Novartis have successively entered the development of nuclear medicine products, with five major international pharmaceutical companies now investing in nuclear medicine product development, along with 38 companies and 45 ongoing clinical trials. Jisheng Life Sciences, established 13 years ago, focuses on nuclear medicine product development, production, and supply, and has seen strong financial growth and operational performance under new management, with plans to move to Hua Gu National Plaza after the stock public offering to create a more energy-efficient and low-carbon corporate office environment in line with ESG principles.
Source: YAHOO